- £218.75bn
- £236.77bn
- $54.07bn
- 78
- 14
- 98
- 73
REG - AstraZeneca PLC - AZN: Year-To-Date and Q3 2017 Results Announcement <Origin Href="QuoteRef">AZN.L</Origin> - Part 2
AnnouncementREG - AstraZeneca PLC - AZN: Year-To-Date and Q3 2017 Results Announcement <Origin Href="QuoteRef">AZN.L</Origin> - Part 1
AnnouncementREG - AstraZeneca PLC - AZN: Year-To-Date and Q3 2017 Results Announcement <Origin Href="QuoteRef">AZN.L</Origin> - Part 3
AnnouncementREG - AstraZeneca PLC - Total Voting Rights <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - ASTRAZENECA AND ASPEN COMPLETE ANAESTHETICS DEAL <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - AstraZeneca tralokinumab update in severe asthma <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - US FDA approves AstraZeneca's Calquence for MCL <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - AZ and MSD rapidly advance Lynparza in Japan <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - US FDA approves Bydureon BCise for type-2 diabetes <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - FDA Priority Review for Lynparza in breast cancer <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - FDA accepts sBLA file for Imfinzi; priority review <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - FDA grants Tagrisso BTD for 1st-line EGFR nsclc <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - Total Voting Rights <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - Aspen acquires remaining rights to AZ anaesthetics <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - IMFINZI superior PFS in Stage III lung cancer <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - Tagrisso potential standard of care in lung cancer <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - Celgene and AZ update on Fusion trial programme <Origin Href="QuoteRef">AZN.L</Origin>
AnnouncementREG - AstraZeneca PLC - AZ Duaklir improves lung function in COPD patients <Origin Href="QuoteRef">AZN.L</Origin>
Announcement